NCT03811002 2026-05-01Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)National Cancer Institute (NCI)Phase 3 Active not recruiting544 enrolled 29 charts